Combined Effects of Oxaliplatin and Tetracaine on Proliferation and Migration in Triple-Negative Breast Cancer

Serife Yerlikaya; Naıma Bınte Shapan; Zeynep Pelin Gov

doi:10.17798/bitlisfen.1896158

Combined Effects of Oxaliplatin and Tetracaine on Proliferation and Migration in Triple-Negative Breast Cancer

Abstract

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by the absence of estrogen, progesterone, and HER2 receptors, presenting significant challenges in treatment due to a lack of targeted therapies. This study investigates the combination effects of oxaliplatin, a platinum-based chemotherapeutic agent, and tetracaine, a sodium channel modulator, on the proliferation and migration of MDA-MB-231 cells, a highly metastatic TNBC cell line. We hypothesized that the combined application of these agents would enhance anti-proliferative and anti-migratory responses through mechanisms that may involve voltage-gated sodium channel-associated pathways linked to tumor invasion. Using cell viability assays, MTT assays, and wound healing assays, we determined the optimal non-toxic concentrations of oxaliplatin and tetracaine and evaluated their individual and combined effects on cell growth and migration. Our findings reveal that the combination treatment significantly reduces cell proliferation and migration compared to either agent alone, indicating a potential therapeutic strategy for TNBC through drug repurposing and combinatorial approaches. These findings provide a rationale for mechanistic dissection of Nav1.5-dependent signaling pathways and support subsequent in vivo validation of this combinatorial strategy in translational TNBC models.

Keywords

Supporting Institution

Istanbul Medipol University Research Institute for Health Sciences and Technologies

Project Number

BAP 2024/51

Thanks

We sincerely thank Istanbul Medipol University for their support of the BAP 2024/51 project.

References

A. Ahmad, Breast Cancer Metastasis and Drug Resistance, 2nd ed., vol. 1152. Cham, Switzerland: Springer International Publishing, 2019. https://doi.org/10.1007/978-3-030-20301-6
M. S. Donepudi, K. Kondapalli, S. J. Amos, and P. Venkateshan, “Breast cancer statistics and markers,” J. Cancer Res. Ther., vol. 10, pp. 506–511, 2014. https://doi.org/10.4103/0973-1482.137927
X. Dai, L. Xiang, and Z. Bai, “Cancer hallmarks, biomarkers and breast cancer molecular subtypes,” J. Cancer, vol. 7, pp. 1281–1294, 2016. https://doi.org/10.7150/jca.13141
R. M. Sareyeldin et al., “Gene expression and miRNAs profiling: Function and regulation in human epidermal growth factor receptor 2 (HER2)-positive breast cancer,” Cancers, vol. 11, p. 646, 2019. https://doi.org/10.3390/cancers11050646
H. Yao et al., “Triple-negative breast cancer: Is there a treatment on the horizon?” Oncotarget, vol. 8, pp. 1913–1924, 2017. https://doi.org/10.18632/oncotarget.12284
L. A. Hoeferlin, C. E. Chalfant, and M. A. Park, “Challenges in the treatment of triple negative and HER2-overexpressing breast cancer,” J. Surg. Sci., vol. 1, no. 1, pp. 3–7, 2013. Available: https://pubmed.ncbi.nlm.nih.gov/24818173/
V. Masoud and G. Pages, “Targeted therapies in breast cancer: New challenges to fight against resistance,” World J. Clin. Oncol., vol. 8, pp. 120–134, 2017. https://doi.org/10.5306/wjco.v8.i2.120
S. Dasari and P. B. Tchounwou, “Cisplatin in cancer therapy: Molecular mechanisms of action,” Eur. J. Pharmacol., vol. 740, pp. 364–378, 2014. https://doi.org/10.1016/j.ejphar.2014.07.025

A. Grothey et al., “Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7,” J. Clin. Oncol., vol. 29, no. 4, pp. 421–427, 2011. https://doi.org/10.1200/JCO.2010.31.5911
W. J. Brackenbury, “Voltage-gated sodium channels and metastatic disease,” Channels, vol. 6, no. 5, pp. 352–361, 2012. https://doi.org/10.4161/chan.21910
H. Kaanoglu et al., “Combinatorial treatment of glioblastoma with temozolomide (TMZ) plus 5-ethynyl-2′-deoxyuridine (EdU),” Proc. Natl. Acad. Sci. U.S.A., vol. 123, no. 1, Art. no. e2532187123, 2026. https://doi.org/10.1073/pnas.2532187123
M. Ribeiro et al., “Human breast cancer cells demonstrate electrical excitability,” Front. Neurosci., vol. 14, p. 404, 2020. https://doi.org/10.3389/fnins.2020.00404
F. Grolleau, L. Gamelin, M. Boisdron-Celle, B. Lapied, M. Pelhate, and E. Gamelin, “A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels,” J. Neurophysiol., vol. 85, no. 5, pp. 2293–2297, 2001. https://doi.org/10.1152/jn.2001.85.5.2293
E. Selçuk et al., “Neuroblastoma: Anti-invasive effects of tetracaine in vitro,” Basic Clin. Pharmacol. Toxicol., vol. 138, no. 3, Art. no. e70190, 2026. https://doi.org/10.1111/bcpt.70190
A. Yerlikaya et al., “A novel combination treatment for breast cancer cells involving BAPTA-AM and proteasome inhibitor bortezomib,” Oncol. Lett., vol. 12, no. 1, pp. 323–330, 2016. https://doi.org/10.3892/ol.2016.4597
D. Keleş, M. Sipahi, Ş. İnanç-Sürer, M. B. Djamgoz, and G. Oktay, “Tetracaine downregulates matrix metalloproteinase activity and inhibits invasiveness of strongly metastatic MDA-MB-231 human breast cancer cells,” Chem.-Biol. Interact., vol. 385, p. 110730, 2023. https://doi.org/10.1016/j.cbi.2023.110730
S. Al-Bahlani, B. Al-Dhahli, K. Al-Adawi, A. Al-Nabhani, and M. Al-Kindi, “Platinum-based drugs differentially affect the ultrastructure of breast cancer cell types,” BioMed Res. Int., vol. 2017, Art. no. 3178794, 2017. https://doi.org/10.1155/2017/3178794
H. B. Kucuk et al., “Novel β hydroxy ketones: Synthesis, spectroscopic characterization, molecular docking, and anticancer activity studies,” J. Mol. Struct., vol. 1250, p. 131772, 2022. https://doi.org/10.1016/j.molstruc.2021.131772
S. Yerlikaya et al., “Investigation of chemical profile, biological properties of Lotus corniculatus L. extracts and their apoptotic-autophagic effects on breast cancer cells,” J. Pharm. Biomed. Anal., vol. 174, pp. 286–299, 2019. https://doi.org/10.1016/j.jpba.2019.05.068
N. Bilani et al., “Breast cancer in the United States: A cross-sectional overview,” J. Cancer Epidemiol., vol. 2020, Art. no. 6387378, 2020. https://doi.org/10.1155/2020/6387378
L. A. Carey et al., “The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes,” Clin. Cancer Res., vol. 13, no. 8, pp. 2329–2334, 2007. https://doi.org/10.1158/1078-0432.CCR-06-1109
M. Viale et al., “Combination of cisplatin-procaine complex DPR with anticancer drugs increases cytotoxicity against ovarian cancer cell lines,” Anti-Cancer Drugs, vol. 9, no. 5, pp. 457–463, 1998. https://doi.org/10.1016/S0959-8049(96)00354-1

Details

Primary Language

English

Subjects

Cancer Biology

Journal Section

Research Article

Authors

Serife Yerlikaya ^*
0000-0002-5349-7298
Türkiye

Naıma Bınte Shapan
0009-0002-2486-0251
Türkiye

Zeynep Pelin Gov
0009-0006-4625-7196
Türkiye

Publication Date

September 30, 2026

Submission Date

February 23, 2026

Acceptance Date

July 9, 2026

Published in Issue

Year 2026 Volume: 15 Number: 3

DOI

https://doi.org/10.17798/bitlisfen.1896158

IZ

https://izlik.org/JA78KT99AU

Cite

RIS / Bibtex

APA

Yerlikaya, S., Shapan, N. B., & Gov, Z. P. (2026). Combined Effects of Oxaliplatin and Tetracaine on Proliferation and Migration in Triple-Negative Breast Cancer. Bitlis Eren Üniversitesi Fen Bilimleri Dergisi, 15(3), 1314-1322. https://doi.org/10.17798/bitlisfen.1896158

AMA

1.Yerlikaya S, Shapan NB, Gov ZP. Combined Effects of Oxaliplatin and Tetracaine on Proliferation and Migration in Triple-Negative Breast Cancer. Bitlis Eren Üniversitesi Fen Bilimleri Dergisi. 2026;15(3):1314-1322. doi:10.17798/bitlisfen.1896158

Chicago

Yerlikaya, Serife, Naıma Bınte Shapan, and Zeynep Pelin Gov. 2026. “Combined Effects of Oxaliplatin and Tetracaine on Proliferation and Migration in Triple-Negative Breast Cancer”. Bitlis Eren Üniversitesi Fen Bilimleri Dergisi 15 (3): 1314-22. https://doi.org/10.17798/bitlisfen.1896158.

EndNote

Yerlikaya S, Shapan NB, Gov ZP (September 1, 2026) Combined Effects of Oxaliplatin and Tetracaine on Proliferation and Migration in Triple-Negative Breast Cancer. Bitlis Eren Üniversitesi Fen Bilimleri Dergisi 15 3 1314–1322.

IEEE

[1]S. Yerlikaya, N. B. Shapan, and Z. P. Gov, “Combined Effects of Oxaliplatin and Tetracaine on Proliferation and Migration in Triple-Negative Breast Cancer”, Bitlis Eren Üniversitesi Fen Bilimleri Dergisi, vol. 15, no. 3, pp. 1314–1322, Sept. 2026, doi: 10.17798/bitlisfen.1896158.

ISNAD

Yerlikaya, Serife - Shapan, Naıma Bınte - Gov, Zeynep Pelin. “Combined Effects of Oxaliplatin and Tetracaine on Proliferation and Migration in Triple-Negative Breast Cancer”. Bitlis Eren Üniversitesi Fen Bilimleri Dergisi 15/3 (September 1, 2026): 1314-1322. https://doi.org/10.17798/bitlisfen.1896158.

JAMA

1.Yerlikaya S, Shapan NB, Gov ZP. Combined Effects of Oxaliplatin and Tetracaine on Proliferation and Migration in Triple-Negative Breast Cancer. Bitlis Eren Üniversitesi Fen Bilimleri Dergisi. 2026;15:1314–1322.

MLA

Yerlikaya, Serife, et al. “Combined Effects of Oxaliplatin and Tetracaine on Proliferation and Migration in Triple-Negative Breast Cancer”. Bitlis Eren Üniversitesi Fen Bilimleri Dergisi, vol. 15, no. 3, Sept. 2026, pp. 1314-22, doi:10.17798/bitlisfen.1896158.

Vancouver

1.Serife Yerlikaya, Naıma Bınte Shapan, Zeynep Pelin Gov. Combined Effects of Oxaliplatin and Tetracaine on Proliferation and Migration in Triple-Negative Breast Cancer. Bitlis Eren Üniversitesi Fen Bilimleri Dergisi. 2026 Sep. 1;15(3):1314-22. doi:10.17798/bitlisfen.1896158